Pfizer Inc.'s advanced kidney cancer treatment may not be effective at prolonging the time some patients live without the disease getting worse, a Food and Drug Administration staff report said today.
The FDA said it was concerned that the number of U.S. patients who benefited from the therapy, chemically known as axitinib, was small. People who showed the most response were first treated with medicines known as cytokines, which are not used as much as newer treatments.
